DDInter1259 DDInter178
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Rosoxacin
Nalidixic acid {u} (Compound) binds {v} (Gene) TDO2
Nalidixic acid {u} (Compound) upregulates {v} (Gene) HERC6
Nalidixic acid {u} (Compound) downregulates {v} (Gene) DHRS7
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Nalidixic acid (Compound) resembles Norfloxacin (Compound)
Nalidixic acid (Compound) resembles Rosoxacin (Compound)
Nalidixic acid (Compound) binds TDO2 (Gene)
Nalidixic acid (Compound) upregulates HERC6 (Gene)
Nalidixic acid (Compound) downregulates DHRS7 (Gene)
Nalidixic acid (Compound) causes Erythema multiforme (Side Effect)